Biotech company Neogap and cancer diagnostics company Simsen Diagnostics have initiated a collaboration aimed at improving personalized cancer diagnostics by examining circulating tumor DNA in the blood of patients participating in Neogap’s Phase I/II clinical trial. The goal is to develop more accurate and efficient diagnostic tools for cancer. Neogap is developing a therapy that identifies so-called neoantigens, which are tumor-specific proteins created as a result of changes in the DNA of tumor cells. The set of these proteins is unique to each patient and distinguishes tumor tissue from healthy tissue. Thus, Neogap can use the identification of neoantigens to target its treatment specifically to the patient’s tumor cells. This provides the potential for a potent tumor-directed therapy that spares healthy tissue. Simsen Diagnostics’ personalized technology can use the same information about the coding sequences behind neoantigens to create molecular tests to monitor the level of cancer in the blood.

Bioteknikbolaget Neogap och cancerdiagnostikbolaget Simsen Diagnostics har inlett ett samarbete inriktat på att förbättra individanpassad cancerdiagnostik genom att undersöka cirkulerande tumör-DNA i blodet hos patienter som deltar i Neogaps kliniska fas I/II-studie. Målet är att utveckla mer precisa och effektiva diagnosverktyg för cancer. Neogap utvecklar en terapi där man identifierar så kallade neoantigener, vilka är tumörspecifika proteiner som skapas till följd av förändringar i tumör cellernas DNA. Uppsättningen av dessa proteiner är unikt för varje patient och särskiljer tumörvävnad från frisk vävnad. På så vis kan Neogap utnyttja identifikationen av neoantigener för att rikta sin behandling specifikt mot patientens tumörceller. Detta ger potential för en potent tumörriktad terapi som skonar frisk vävnad. Simsen Diagnostik individanpassade teknik kan med samma information om de kodande sekvenserna bakom neoantigener skapa molekylära tester för att följa nivån av cancern i blodet. För varje patient väljs 15-30 unika förändringar ut för att skapa ett personligt

Gothenburg 2022-12-06 Simsen Diagnostics AB and Oncorena AB have entered into an agreement, where Simsen Diagnostics will measure circulating tumor DNA in Oncorena’s clinical phase I-II kidney cancer study. Simsen Diagnostics will design individualized tests that follow a unique mutation signature in each patient. The method is up to ten times more sensitive than conventional techniques for measuring tumor DNA in blood, which contributes to better monitoring of the treatment effect. Oncorena is developing a potentially breakthrough treatment for patients with advanced kidney cancer. The drug candidate orellanine, which has a unique mechanism of action, is being developed for organ-specific chemotherapy with potential curative benefits for patients with advanced kidney cancer undergoing dialysis due to kidney failure. The drug candidate’s potential will now also be evaluated by measuring changes in the level of circulating tumor DNA in the patient’s blood. Recruitment of patients is ongoing and currently patients from Sweden,